We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Stockal+Disclaimer.pdf
2 own
3 watching
Current Price
$22.44
$1.67
(8.04%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
990.64M
52-Week High
32.71000
52-Week Low
14.30500
Average Volume
0.22M
Dividend Yield
--
P/E Ratio
--
Market Capitalization990.64M52-Week High32.7100052-Week Low14.30500Average Volume0.22MDividend Yield--P/E Ratio--What does the Stockal+Disclaimer.pdf do?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company s therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
PR Newswire
7 months ago
Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials PR...
Zolmax
8 months ago
Inhibrx, Inc. (NASDAQ:INBX Get Rating) Analysts at Jefferies Financial Group issued their FY2024 earnings per share estimates for Inhibrx in a research report issued to clients and investors on Monday, March 6th. Jefferies Financial Group analyst M. Yee expects that the company will earn ($3.55) per...
Ticker Report
10 months ago
Inhibrx, Inc. (NASDAQ:INBX Get Rating) insider Brendan P. Eckelman sold 28,750 shares of the businesss stock in a transaction dated Wednesday, February 1st. The shares were sold at an average price of $24.73, for a total value of $710,987.50. Following the completion of the sale, the ...
Zolmax
10 months ago
Inhibrx, Inc. (NASDAQ:INBX Get Rating) CEO Mark Lappe sold 21,665 shares of the firms stock in a transaction dated Monday, January 23rd. The stock was sold at an average price of $25.36, for a total transaction of $549,424.40. Following the completion of the sale, the chief executive officer now ...
Ticker Report
10 months ago
Inhibrx, Inc. (NASDAQ:INBX Get Rating) CEO Mark Lappe sold 21,665 shares of Inhibrx stock in a transaction that occurred on Monday, January 23rd. The stock was sold at an average price of $25.36, for a total transaction of $549,424.40. Following the completion of the transaction, the chief ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
Can Indians buy Stockal+Disclaimer.pdf shares?
How can I buy Stockal+Disclaimer.pdf shares from India?
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
What is today’s traded volume of Stockal+Disclaimer.pdf?
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
Current Price
$22.44
$1.67
(8.04%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.